Procter & Gamble Q3 earnings top estimates; raises FY22 top-line guidance
Procter & Gamble Q3 earnings top estimates; raises FY22 top-line guidance
Adjusted EPS of $1.33 beat the consensus of $1.30.$Procter & Gamble(PG.US)$ reported third-quarter FY22 sales growth of 7.1% year-on-year to $19.38 billion, beating the consensus of $18.73 billion.
Organic sales increased 10%, driven by a 3% increase in shipment volume, 5% from improved pricing, and a 2% increase from geographic and product mix.
Sales in the beauty segment rose 2%, the Grooming segment expanded 3%, and Health Care jumped 13%.
Adjusted EPS of $1.33 beat the consensus of $1.30.
Gross profit decreased 1% Y/Y to $9.1 billion. Gross margin decreased by 400 basis points to 46.7%.
Operating margin contracted 10 basis points to 20.8%, while operating income for the quarter rose 6% to $4.02 billion.
P&G held $8.5 billion in cash and equivalents as of March 31, 2022.
Outlook: P&G raised FY22 all-in sales growth outlook to 4% - 5% (previously 3% - 4%).
The company continues to expect FY22 core EPS growth of 3% - 6% versus FY21 Core EPS of $5.66.
P&G also expects to pay over $8 billion in dividends and repurchase $10 billion of common shares in FY22.
$寶潔(PG.US)$該公司公佈的22財年第三季度銷售額同比增長7.1%，達到193億美元，超出了187.3億美元的共識。
有機產品銷售額增長了10%，其中發貨量增長了3%，定價提高了5%，地域和產品組合增長了2%。
美容領域的銷售額增長了2%，美容領域增長了3%，醫療保健領域增長了13%。
調整後的每股收益為1.33美元，超過了1.30美元的共識。
毛利潤同比下降1%，至91億美元。毛利率下降400個基點至46.7%。
營業利潤率收縮10個基點，至20.8%，而本季度營業收入增長6%，至40.2億美元。
寶潔 截至2022年3月31日，持有85億美元的現金和等價物。
展望：寶潔將22財年整體銷售增長預期上調至4%-5%(之前為3%-4%)。
該公司繼續預計22財年核心每股收益增長3%-6%，而21財年核心每股收益增長5.66美元。
寶潔還預計在22財年支付超過80億美元的股息，並回購100億美元的普通股。
